Home › Funds › Spruce Street Capital LP › ELVN

Spruce Street Capital LP position in ELVN

ENLIVEN THERAPEUTICS INC · Health Care

Spruce Street Capital LP reported holding 329,006 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$15.1M, representing 2.40% of its reported portfolio and ranking #13 among its reported holdings. Spruce Street Capital LP has disclosed ELVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)329.01K sh
Reported value held$15.08M
Portfolio Weight2.40%
First reportedQ4 2025
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Spruce Street Capital LP's ELVN position evolved

Spruce Street Capital LP first disclosed a stake in ELVN in Q4 2025 at 446,084 shares (US$6.9M). The position peaked in Q2 2026 at 329,006 shares, worth US$16.7M. Across 4 filings, Spruce Street Capital LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 329,006 shares valued at US$15.1M. Notable position changes include a 26% trim in Q1 2026 (shares rose 29% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 446.08K $6.87M New
Q1 2026 329.01K $12.90M Reduce
Q2 2026 329.01K $16.70M Hold
Q3 2026 329.01K $15.08M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →

FAQ

How long has Spruce Street Capital LP held ELVN?

Spruce Street Capital LP has disclosed ELVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Spruce Street Capital LP's current position in ELVN?

As of Q3 2026, Spruce Street Capital LP holds 329.01K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $15.08M, representing 2.40% of its reported portfolio and ranking #13.

Has Spruce Street Capital LP been buying or selling ELVN?

In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in ELVN. The position peaked in Q2 2026 at 329.01K shares.

Which other funds hold ELVN?

Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.